Free shipping on all orders over $ 500

E6005

Cat. No. M6153

All AbMole products are for research use only, cannot be used for human consumption.

E6005 Structure
Synonym:

RVT-501

Size Price Availability Quantity
5mg USD 88  USD88 In stock
10mg USD 138  USD138 In stock
50mg USD 400  USD400 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

In vitro: RVT-501 potently and selectively inhibits human PDE4 activity with an IC50 of 2.8 nM and suppresses the production of various cytokines from human lymphocytes and monocytes with IC50 values ranging from 0.49 to 3.1 nM.

In vivo: RVT-501 is currently in phase 2 development for patients with mild-to-moderate atopic dermatitis. In mice models, the topical application of RVT-501 produces an immediate antipruritic effect as well as an anti-inflammatory effect with reduced expression of cytokines/adhesion molecules. On the basis of these observed effects, topical RVT-501 ameliorates the appearance of atopic dermatitis-like skin lesions in two types of AD models, hapten- and mite-elicited models, exhibiting inhibitory effects comparable to that of tacrolimus.

Protocol (for reference only)
Cell Experiment
Cell lines
Preparation method
Concentrations
Incubation time
Animal Experiment
Animal models NC/Nga mice
Formulation 4% SDS solution
Dosages 10 μl/g
Administration s.c.
Chemical Information
Molecular Weight 472.49
Formula C26H24N4O5
CAS Number 947620-48-6
Solubility (25°C) 100 mg/mL in DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Mano Y, et al. J Chromatogr B Analyt Technol Biomed Life Sci. Validation of a UPLC-MS/MS method for the simultaneous determination of E6005, a phosphodiesterase 4 inhibitor, and its metabolite in human plasma.

[2] Ishii N, et al. J Pharmacol Exp Ther. Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model.

Related PDE Products
MR-L2

MR-L2 is a reversible and noncompetitive allosteric activator of long-isoform phosphodiesterase-4 (PDE4), activates representative PDE4 long-isoform variants (PDE4A4, PDE4B1, PDE4C3, PDE4D5). MR-L2 suppresses PGE2-induced MDCK cell cyst formation with an EC50 of 1.2 μM.

MMPX

MMPX is a potent PDE1 inhibitor.

T-0156 

T-0156 is a potent and selective phosphodiesterase type 5 (PDE5) inhibitor.

TPN171 

TPN171 is a potent, selective and oral bioavailable inhibitor of phosphodiesterase type 5 (PDE5) with an IC50 of 0.62 nM, being developed for the treatment of pulmonary arterial hypertension (PAH).

Mesopram

Mesopram (Daxalipram) is an orally active phosphodiesterase (PDE) 4 inhibitor.

  Catalog
Abmole Inhibitor Catalog




Keywords: E6005, RVT-501 supplier, PDE, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.